Platelet GSK3B activity in patients with late-life depression: Marker of depressive episode severity and cognitive impairment?

Nenhuma Miniatura disponível
Citações na Scopus
39
Tipo de produção
article
Data de publicação
2011
DOI
Scopus
Web of Science
PubMed
Título da Revista
ISSN da Revista
Título do Volume
Editora
INFORMA HEALTHCARE
Autores
PAULA, Vanessa Rodrigues Jesus de
Citação
WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY, v.12, n.3, p.216-222, 2011
Projetos de Pesquisa
Unidades Organizacionais
Fascículo
Resumo
Objective. Increased GSK3B activity has been reported as a state marker of major affective episodes in patients with depression and bipolar disorder. No study so far has addressed GSK3B activity in late-life depression. The aims of the present study were to determine GSK3B activity in platelets of elderly patients with major depression, and the association between GSK3B activity and the severity of depressive symptoms and cognitive impairment. Methods. Forty drug-free elderly patients with major depressive episode were compared to healthy older adults (n == 13). Severity of the depressive episode and current cognitive state were determined by the Hamilton Depression Scale (HAM-D) and the Cambridge Cognitive Test (CAMCOG), respectively. Total- and ser-9-phosphorylated GSK3B (tGSK3B and pGSK3B) were determined in platelets by enzyme immunometric assays (EIA). GSK3B activity was indirectly inferred by the GSK3B ratio (i.e. pGSK3B/tGSK3B). Results. Elderly depressed patients had significantly lower pGSK3B levels (P == 0.03) and GSK3B ratio (P == 0.03), indicating higher GSK3B activity. Higher GSK3B activity were observed in patients with severe depressive episode (HAM-D scores > 22, P == 0.03) and with cognitive impairment (CAMCOG scores < 86, P == 0.01). Conclusion. The present findings provide additional evidence of the involvement of GSK3B in the pathophysiology of late-life major depression. Higher GSK3B activity may be more relevant in those patients with more severe depressive symptoms and cognitive impairment.
Palavras-chave
Late-life depression, glycogen synthase kinase 3-beta, physiopathology, biological markers, cognition
URI
https://observatorio.fm.usp.br/handle/OPI/23412
Referências
  1. Beaulieu JM, 2008, P NATL ACAD SCI USA, V105, P1333, DOI 10.1073/pnas.0711496105
  2. Prickaerts J, 2006, J NEUROSCI, V26, P9022, DOI 10.1523/JNEUROSCI.5216-05.2006
  3. HAMILTON M, 1960, J NEUROL NEUROSUR PS, V23, P56, DOI 10.1136/jnnp.23.1.56
  4. Polter A, 2010, NEUROPSYCHOPHARMACOL, V35, P1761, DOI 10.1038/npp.2010.43
  5. Li XH, 2007, INT J NEUROPSYCHOPH, V10, P7, DOI 10.1017/S1461145706006547
  6. WANG QM, 1994, J BIOL CHEM, V269, P14566
  7. Gould TD, 2004, INT J NEUROPSYCHOPH, V7, P387, DOI 10.1017/S1461145704004535
  8. Diniz BS, 2008, REV BRAS PSIQUIATR, V30, P316, DOI 10.1590/S1516-44462008000400003
  9. Peineau S, 2008, BRIT J PHARMACOL, V153, pS428, DOI 10.1038/bjp.2008.2
  10. Li XH, 2004, NEUROPSYCHOPHARMACOL, V29, P1426, DOI 10.1038/sj.npp.1300439
  11. Hirashima Y, 2003, J ENDOCRINOL, V179, P253, DOI 10.1677/joe.0.1790253
  12. Jope RS, 2007, NEUROCHEM RES, V32, P577, DOI 10.1007/s11064-006-9128-5
  13. Krishnan V, 2008, BIOL PSYCHIAT, V64, P691, DOI 10.1016/j.biopsych.2008.06.003
  14. Karege F, 2007, BIOL PSYCHIAT, V61, P240, DOI 10.1016/j.biopsych.2006.04.036
  15. Jope RS, 2004, TRENDS BIOCHEM SCI, V29, P95, DOI 10.1016/j.tibs.2003.12.004
  16. Forlenza OV, 2011, J PSYCHIATR RES, V45, P220, DOI 10.1016/j.jpsychires.2010.06.002
  17. Pandey GN, 2010, J PSYCHIATR RES, V44, P143, DOI 10.1016/j.jpsychires.2009.07.009
  18. Klein PS, 1996, P NATL ACAD SCI USA, V93, P8455, DOI 10.1073/pnas.93.16.8455
  19. RYLATT DB, 1980, EUR J BIOCHEM, V107, P529
  20. Diniz BS, 2010, AM J GERIAT PSYCHIAT, V18, P172, DOI 10.1097/JGP.0b013e3181c2947f
  21. Jope RS, 2006, CURR DRUG TARGETS, V7, P1421
  22. [Anonymous], 2000, DIAGNOSTIC STAT MANU
  23. Hye A, 2005, NEUROSCI LETT, V373, P1, DOI 10.1016/j.neulet.2004.10.031
  24. Mai L, 2002, J NEUROCHEM, V82, P75, DOI 10.1046/j.1471-4159.2002.00939.x
  25. Teixeira AL, 2010, BIOMARK MED, V4, P871, DOI [10.2217/bmm.10.111, 10.2217/BMM.10.111]
  26. Grimes CA, 2001, PROG NEUROBIOL, V65, P391, DOI 10.1016/S0301-0082(01)00011-9
  27. Kumamaru E, 2008, MOL ENDOCRINOL, V22, P546, DOI 10.1210/me.2007-0264
  28. Barbosa NR, 2007, EUR ARCH PSY CLIN N, V257, P340, DOI 10.1007/s00406-007-0736-0
  29. Barry FA, 2003, FEBS LETT, V553, P173, DOI 10.1016/S0014-5793(03)01015-9
  30. Diniz BS, 2010, J PSYCHIATR RES, V44, P917, DOI 10.1016/j.jpsychires.2010.02.008
  31. Diniz BS, 2010, WORLD J BIOL PSYCHIA, V11, P550, DOI 10.3109/15622970903544620
  32. EMBI N, 1979, EUR J BIOCHEM, V100, P339, DOI 10.1111/j.1432-1033.1979.tb04176.x
  33. First M. B., 2002, STRUCTURED CLIN INTE
  34. FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6
  35. Forlenza OV, 2010, REV BRAS PSIQUIATR, V32, P216, DOI 10.1590/S1516-44462010005000002
  36. Gattaz WF, 2004, J NEURAL TRANSM, V111, P591, DOI 10.1007/s00702-004-0142-y
  37. Kaidanovich-Beilin O, 2004, BIOL PSYCHIAT, V55, P781, DOI 10.1016/j.biopsych.2004.01.008
  38. Lauterbach E, 2006, J AFFECT DISORDERS, V91, P57, DOI 10.1016/j.jad.2005.11.016
  39. Li XH, 2007, BIOL PSYCHIAT, V61, P216, DOI 10.1016/j.biopsych.2006.02.027
  40. Nunes PV, 2008, INT J GERIATR PSYCH, V23, P1127, DOI 10.1002/gps.2038
  41. Pan A, 2008, J AFFECT DISORDERS, V109, P75, DOI 10.1016/j.jad.2007.11.002
  42. ROTH M, 1986, BRIT J PSYCHIAT, V149, P698, DOI 10.1192/bjp.149.6.698

Coleções
Artigos e Materiais de Revistas Científicas - FM/MPS
Artigos e Materiais de Revistas Científicas - HC/IPq
Artigos e Materiais de Revistas Científicas - LIM/27